Teva Pharmaceutical and Samsung Bioepis Forge Global Biosimilar Partnership (TEVA)

As reported by gurufocus.com

On October 01, 2026, Teva Pharmaceutical Industries Ltd (NYSE: TEVA) announced a strategic global agreement with Samsung Bioepis Co., Ltd. to develop and commer...

▸ MARKET SAMACHAR VIEW

NEUTRAL

Read full article on gurufocus.com ↗

Market Samachar is a news aggregator. This article was originally published by gurufocus.com. Tap the button above to read the full story on their site.

INDIAN Inox Clean Energy IPO papers kept in abeyance by Sebi Markets-Economic Times
COMPANIES Sebi asks stock brokers to display investor warnings on apps and websites Stocks-Markets-Economic Times
INDIAN Carlsberg India IPO gets Sebi approval along with three other public offers. Check details Markets-Economic Times
COMPANIES Bharat Dynamics among 5 capital goods stocks that hit 52-week lows and slipped up to 17% in a month Stocks-Markets-Economic Times
INDIAN Accenture sets annual revenue growth forecast at 3-6%, above estimates Markets-Economic Times
INDIAN 45% YTD rally! Experts see up to 56% upside in these 3 stocks on China's export shift | Target, rationale mint - markets
INDIAN Azad Engineering share price: Up 86% in 6 months! Is more steam left in this defence stock? Experts' view, target price mint - markets
INDIAN Infosys, Wipro ADRs jump up to 10% after Accenture Q4 results beat Wall Street estimates mint - markets

Teva Pharmaceutical and Samsung Bioepis Forge Global Biosimilar Partnership (TEVA)

More from Market Samachar